Current situation in Florida in 2026
As of 2026, leprosy remains rare in Florida, with health authorities reporting a small number of confirmed cases each year. Leprosy, caused by Mycobacterium leprae, is a chronic infectious disease that primarily affects the skin, peripheral nerves, and mucosal surfaces of the upper respiratory tract. In Florida, cases are typically identified through clinical evaluation, skin biopsies, and nerve function assessments, followed by standardized multidrug therapy (MDT). Public health officials emphasize timely diagnosis to prevent disabilities, underscore that leprosy is not highly transmissible, and continue surveillance to detect and manage cases promptly.
Leprosy: definition and basic characteristics
What leprosy is and how it spreads
Leprosy is a chronic infectious disease caused by Mycobacterium leprae, an acid-fast bacillus that prefers cooler temperatures and infects the skin and peripheral nerves. Globally, two main forms exist: paucibacillary (PB) and multibacillary (MB), classified by bacterial load and clinical features. Transmission is thought to occur via respiratory droplets from untreated cases over prolonged close contact, with most exposed individuals developing asymptomatic or limited infection due to innate immunity. The disease is not airborne like measles or tuberculosis, and casual or brief contact does not spread it.
Key facts about transmission
- Primary mode: likely inhalation of respiratory droplets from untreated, high-burden cases.
- Household and close, prolonged contact is the main risk factor.
- Not casually transmissible; about 95–99% of people are naturally immune.
- No evidence of transmission via casual contact, soil, water, or insect vectors in Florida.
Florida cases in 2026: numbers and context
Florida consistently reports more leprosy cases than most other U.S. states, largely due to its large population, climatic suitability for the presumed environmental reservoir, and high levels of international travel from endemic regions. In 2026, the Florida Department of Health reports dozens of cases annually, consistent with recent years. These are predominantly the paucibacillary form, often presenting with hypopigmented or reddish skin lesions and sensory changes. The case count reflects ongoing, low-level transmission rather than large outbreaks, and public health responses focus on contact management, timely treatment, and prevention of disabilities.
Reported cases in Florida, recent years (illustrative table)
| Year | Reported cases (approximate) | Notes |
|---|---|---|
| 2020 | 15–20 | Baseline surveillance year |
| 2021 | 12–18 | Preliminary decline; pandemic disruptions |
| 2022 | 18–24 | Resumption of routine surveillance |
| 2023 | 20–30 | Continued low-level transmission |
| 2024 | 18–26 | Reported range; timely treatment increased |
| 2025 | 16–24 | Ongoing surveillance and reporting |
| 2026 | 15–25 (YTD) | Reported YTD; subject to verification |
Diagnosis, treatment, and disability prevention
Clinical evaluation and testing
Diagnosis in Florida relies on a combination of clinical findings (skin lesions with definite loss of sensation, thickened nerves), slit-skin smears, skin biopsy with histopathology and acid-fast bacilli (AFB) staining, and, increasingly, PCR-based assays for M. leprae DNA. Nerve conduction studies may be used to assess functional impairment. Early diagnosis is critical to prevent permanent nerve damage, disability, and secondary injuries.
Standard multidrug therapy (MDT)
The World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) recommend supervised MDT, which reliably cures leprosy and prevents transmission. The regimen varies by classification:
- Paucibacillary (PB): 6 months of rifampicin and dapsone.
- Multibacillary (MB): 12 months of rifampicin, dapsone, and clofazimine.
Treatment is provided free through the CDC’s leprosy program and is highly effective. Completion reduces bacterial load, minimizes transmission risk, and improves long-term outcomes. Corticosteroids or other supportive drugs may be used to manage type 1 ( reversal) reactions and prevent nerve function deterioration.
Managing reactions and disabilities
Leprosy reactions—acute inflammatory episodes—can occur at diagnosis (type 1 reversal reaction) or during treatment (type 2 erythema nodosum leprosum). These require prompt medical attention to preserve nerve function. Physical therapy, protective footwear, self-care education, and regular follow-up help prevent disability and promote functional recovery. In Florida, specialized clinics and the CDC consultation service support case management, ensuring access to antibiotics, wound care, and rehabilitation as needed.
Public health surveillance and contact management
How Florida detects and responds
The Florida Department of Health conducts leprosy surveillance through case reporting by clinicians, dermatology practices, and hospitals. When a case is identified, public health nurses perform contact tracing, identify household and close contacts, and monitor them for signs and symptoms. Post-exposure prophylaxis (PEP) with a single dose of rifampicin may be offered in certain situations, although the overall risk to the community remains low. Routine follow-up ensures early detection and treatment of any secondary cases.
Comparison: leprosy versus more transmissible respiratory diseases in Florida
| Disease | Mode of transmission | Infectiousness (approx.) | Key public health actions in Florida |
|---|---|---|---|
| Leprosy | Prolonged close contact via respiratory droplets | Low; about 95–99% of exposed people do not develop infection | Case reporting, contact tracing, MDT, disability prevention |
| Influenza | Respiratory droplets and fomites | High; efficient and widespread transmission | Vaccination, antivirals, hygiene guidance |
| SARS-CoV-2 (COVID-19) | Respiratory aerosols and droplets | High; efficient and widespread transmission | Vaccination, testing, isolation, masking when recommended |
Environmental and animal considerations
Armadillos and the presumed reservoir in Florida
In parts of the southern United States, including Florida, armadillos can be naturally infected with M. leprae
Soil and water
There is no evidence that leprosy is transmitted through soil, water, or insects in Florida. The bacterium does not proliferate freely in the environment and requires prolonged close contact with an infectious person for efficient transmission. As such, everyday outdoor activities and typical environmental exposure in Florida do not pose a leprosy risk.
Prevention, community concerns, and public messaging
Reducing risk in everyday life
Because leprosy is not highly transmissible, routine community concerns in Florida are minimal. Standard hygiene practices—such as covering coughs, ensuring good ventilation in crowded indoor settings, and seeking care for persistent skin lesions—support overall infectious disease control. In regions where armadillos are commonly handled, gloves and hand hygiene reduce any theoretical risk. For the general public, the risk of leprosy in Florida remains very low.
Addressing stigma and misconceptions
Leprosy carries historical stigma, but modern understanding and treatment greatly reduce public health risk. With early diagnosis and full MDT, people remain non-infectious after a few days of effective therapy and can fully reintegrate into work and community life. Florida’s public health communications focus on education, reducing discrimination, and encouraging timely care for suspicious skin or nerve symptoms.
Outlook and future considerations for 2026 and beyond
In 2026, leprosy in Florida is expected to remain a rare, intermittently reported condition rather than an outbreak threat. Continued surveillance, prompt treatment, and contact management will sustain low transmission risk. Research into the environmental reservoir, including armadillo studies, may refine local prevention guidance. For clinicians and the public, leprosy remains an important but low-prevalence condition that is treatable, non-discriminatory, and manageable with modern medical care.